Diabetes Alliance Projects

FORGE AHEAD

FORGE AHEAD is a five-year research program (2013-2017) seeking to develop and evaluate community-driven, culturally relevant, primary healthcare models that enhance chronic disease management and appropriate access to available services in First Nations communities across Canada. Developed and implemented by a strong multi-disciplinary and cross-jurisdictional team from 8 provinces, the program uses a participatory research approach that simultaneously ensures culturally appropriate implementation and integrates knowledge translation by involving relevant stakeholders throughout the entire program.

SOAR: Pathway to Wellness

SOAR – Pathway to Wellness is –a three-year research program (2017-2020) seeking to improve the health and health equity of Indigenous peoples by working with communities and organizations as equal partners in a community-driven, community-paced and culturally-relevant program. The aim of the program is to build off the lessons from FORGE AHEAD to strengthen the effectiveness and scalability of a promising Quality Improvement (QI) program that fosters community-initiated innovations to improve diabetes management and prevention in First Nations Communities.

InHypo-DM Project

Some pharmacological therapy used to manage diabetes can increase a patient’s risk of hypoglycemia. Hypoglycemia is the most common diabetes-related adverse event, and so the aim of this study is to develop a survey that will explores Canadians’ clinical and personal perspectives and practices related to hypoglycemia and its impact on the management of diabetes. The survey will be founded on the Theoretical Domains Framework (TDF) developed by Cane et al. (2012), the Diabetes Evaluation Framework for Innovative National Evaluations (DEFINE) and a comprehensive knowledge translation (KT) approach and will be administered to people with diabetes, their family members, and care providers.

iNPHORM Study

The iNPHORM study is one of the first prospective, longitudinal investigations in the world to be conducted in the area of hypoglycemia. The study seeks to develop hypoglycemia risk prediction models that can be applied across diverse clinical settings and patient populations. The real-world models are intended to support health-care providers in identifying and predicting which patients with diabetes are at highest risk of experiencing hypoglycemia.

EASi-PROTKT: A 2-3 year study to find out whether a medicine called vicadrostat when used with a medication called empagliflozin helps people with type 2 diabetes, high blood pressure, and cardiovascular disease. The purpose of this study is to find out whether the study medication helps reduce the development of serious health conditions such as the heart failure, heart attack or stroke. 

EFFICIENT: A 1 year research study to see how well weekly insulin icodec (Awiqli) maintains blood sugar levels compared to daily basal insulins in adults with type 2 diabetes. Approximately 586 people will be participating across Europe and Canada.

ONWARDS 11: An 8 month research study to see how a weekly insulin, insulin icodec (Awiqli), helps in reducing blood sugar compared to daily insulin glargine, both in combination with insulin aspart, in adults with type 1 diabetes. The information collected can help us better understand Type 1 diabetes or related diseases, how the study medicine works in the body,  and how to improve the treatment of people with type 1 diabetes or related diseases. Approximately 830 people worldwide will be participating in this study.

PROMISE:  A 15 year observational (no study medication) study of approximately 800-1000 individuals age 30 and older (18 and older for Aboriginal subjects) at high risk for glucose intolerance. After the 15 year study period, there will be long term follow up through record linkage to the Canadian Institute of Health Information and the Statistics Canada vital statistics databases, both of which are standard methods for determining whether hospitalizations or deaths have occurred among participants. The overall objective of the PROMISE study is to understand the determinants of obesity, impaired fasting glucose, impaired glucose tolerance, T2DM and associated metabolic abnormalities, including insulin resistance, beta cell dysfunction and microalbuminuria.

TRIUMPH OUTCOMES: A 2-3 year study to investigate the effect of the study drug, retatrutide, on the incidence of major adverse cardiovascular events and major adverse kidney events in participants with body mass index (BMI) ≥27 kg/m2 and cardiovascular disease and/or chronic kidney disease. The study aims to learn whether retatrutide can work better than placebo in reducing the risk of major heart related events and reducing the risk of major kidney related events. Approximately 10,000 participants are taking part in the study worldwide.

VICTORION-1 PREVENT: A 4-6 year study to evaluate the effect of the study drug, Inclisiran, on preventing major cardiovascular events (such as heart attacks and strokes) in high-risk patients who have not had a major cardiovascular event and who have high cholesterol. They study drug has been shown to be safe and effective at lowering LDL-cholesterol (bad cholesterol). This study will help understand if a reduction in LDL-cholesterol with Inclisiran will also prevent these important cardiovascular events from occurring. Approximately 14,000 participants will join the study worldwide.